WO2018097628A3 - 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법 - Google Patents

신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법 Download PDF

Info

Publication number
WO2018097628A3
WO2018097628A3 PCT/KR2017/013444 KR2017013444W WO2018097628A3 WO 2018097628 A3 WO2018097628 A3 WO 2018097628A3 KR 2017013444 W KR2017013444 W KR 2017013444W WO 2018097628 A3 WO2018097628 A3 WO 2018097628A3
Authority
WO
WIPO (PCT)
Prior art keywords
neural
stem cells
protecting
regeneration
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/013444
Other languages
English (en)
French (fr)
Other versions
WO2018097628A2 (ko
Inventor
최강열
김미연
한성호
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shine Biopharma Inc
Original Assignee
Shine Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2018554751A priority Critical patent/JP6663509B2/ja
Priority to KR1020207013080A priority patent/KR20200056465A/ko
Priority to DK17874605.3T priority patent/DK3425390T3/da
Priority to SG11201903725UA priority patent/SG11201903725UA/en
Priority to MX2019006040A priority patent/MX379222B/es
Priority to EA201990953A priority patent/EA038404B1/ru
Priority to CA3041245A priority patent/CA3041245C/en
Priority to NZ754020A priority patent/NZ754020A/en
Priority to KR1020217023789A priority patent/KR102519796B1/ko
Priority to KR1020187001715A priority patent/KR101892457B1/ko
Priority to CN202210691469.9A priority patent/CN115025225A/zh
Priority to ES17874605T priority patent/ES2848720T3/es
Priority to CN201780003031.4A priority patent/CN109073634B/zh
Priority to EP17874605.3A priority patent/EP3425390B1/en
Priority to BR112019009711A priority patent/BR112019009711A2/pt
Application filed by Shine Biopharma Inc filed Critical Shine Biopharma Inc
Priority to KR1020187017867A priority patent/KR102114017B1/ko
Priority to AU2017363804A priority patent/AU2017363804B2/en
Priority to MYPI2019002759A priority patent/MY194462A/en
Priority to EP20204059.8A priority patent/EP3800471A1/en
Priority to US15/897,138 priority patent/US10485802B2/en
Publication of WO2018097628A2 publication Critical patent/WO2018097628A2/ko
Publication of WO2018097628A3 publication Critical patent/WO2018097628A3/ko
Priority to IL266573A priority patent/IL266573B/en
Priority to PH12019501143A priority patent/PH12019501143A1/en
Priority to ZA2019/03226A priority patent/ZA201903226B/en
Anticipated expiration legal-status Critical
Priority to US16/545,438 priority patent/US11147816B2/en
Priority to US17/463,219 priority patent/US11701360B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)

Abstract

본 발명은 신경재생이 필요한 환자에게 MEK 1/2 억제제를 투여하는 것을 포함하는, 신경재생을 유도하는 방법에 관한 것이다. 특히 본 발명의 방법에서 MEK 1/2 억제제는 신경줄기세포를 신경세포로 분화시키거나 베타아밀로이드에 의한 세포독성으로부터 신경세포 및 신경줄기세포를 보호하거나, 둘 다에 의해 신경재생을 유도한다. 또한 본 발명은 MEK 1/2 억제제를 투여하는 것을 포함하는, 신경세포의 손실 또는 손상으로부터 신경세포를 보호하는 방법에 관한 것이다. 추가적으로, 본 발명은 신경세포의 손실 또는 손상에 의해 발생하는 신경퇴행성질환의 예방 또는 치료가 필요한 환자에게 상기 MEK 1/2 억제제를 투여하는 것을 포함하는, 신경세포의 손실 또는 손상에 의해 발생하는 신경퇴행성 질환의 예방 또는 치료 방법에 관한 것이다.
PCT/KR2017/013444 2016-11-25 2017-11-23 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법 Ceased WO2018097628A2 (ko)

Priority Applications (25)

Application Number Priority Date Filing Date Title
BR112019009711A BR112019009711A2 (pt) 2016-11-25 2017-11-23 método de indução de neuro-regeneração, método de proteção de neurônios contra perda ou dano neuronal, método de prevenção ou tratamento de doença neurodegenerativa devido à perda ou dano neuronal, e método de triagem de candidatos de fármaco para o tratamento de doenças neurodegenerativas
DK17874605.3T DK3425390T3 (da) 2016-11-25 2017-11-23 Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf
SG11201903725UA SG11201903725UA (en) 2016-11-25 2017-11-23 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
MX2019006040A MX379222B (es) 2016-11-25 2017-11-23 Composición para promover la diferenciación y protección de células madre neurales y método para inducir la regeneración neural usando las mismas.
EA201990953A EA038404B1 (ru) 2017-03-22 2017-11-23 Применение траметиниба для лечения нейродегенеративного заболевания, вызванного утратой или повреждением нейронов
CA3041245A CA3041245C (en) 2016-11-25 2017-11-23 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
NZ754020A NZ754020A (en) 2016-11-25 2017-11-23 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
KR1020217023789A KR102519796B1 (ko) 2016-11-25 2017-11-23 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법
KR1020187001715A KR101892457B1 (ko) 2016-11-25 2017-11-23 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법
CN202210691469.9A CN115025225A (zh) 2016-11-25 2017-11-23 用于诱导神经干细胞的分化和保护的组合物及使用该组合物诱导神经再生的方法
ES17874605T ES2848720T3 (es) 2016-11-25 2017-11-23 Composición para promover la diferenciación y la protección de células madre neurales y método para inducir la regeneración neural utilizando la misma
CN201780003031.4A CN109073634B (zh) 2016-11-25 2017-11-23 用于诱导神经干细胞的分化和保护的组合物及使用该组合物诱导神经再生的方法
EP17874605.3A EP3425390B1 (en) 2016-11-25 2017-11-23 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
JP2018554751A JP6663509B2 (ja) 2016-11-25 2017-11-23 神経幹細胞の分化促進用及び保護用の組成物、並びにそれを利用して神経再生を誘導する方法
KR1020187017867A KR102114017B1 (ko) 2016-11-25 2017-11-23 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법
KR1020207013080A KR20200056465A (ko) 2016-11-25 2017-11-23 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법
AU2017363804A AU2017363804B2 (en) 2016-11-25 2017-11-23 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
MYPI2019002759A MY194462A (en) 2016-11-25 2017-11-23 Composition for Promoting Differentiation of and Protecting Neural Stem Cells and Method for Inducing Neural Regeneration using same
EP20204059.8A EP3800471A1 (en) 2016-11-25 2017-11-23 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
US15/897,138 US10485802B2 (en) 2016-11-25 2018-02-14 Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition
IL266573A IL266573B (en) 2016-11-25 2019-05-12 A preparation for promoting the differentiation and protection of neural stem cells and a method for inducing neural regeneration using it
PH12019501143A PH12019501143A1 (en) 2016-11-25 2019-05-22 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
ZA2019/03226A ZA201903226B (en) 2016-11-25 2019-05-22 Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
US16/545,438 US11147816B2 (en) 2016-11-25 2019-08-20 Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition
US17/463,219 US11701360B2 (en) 2016-11-25 2021-08-31 Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2016-0158739 2016-11-25
KR20160158739 2016-11-25
KR10-2017-0036268 2017-03-22
KR20170036268 2017-03-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/897,138 Continuation US10485802B2 (en) 2016-11-25 2018-02-14 Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition

Publications (2)

Publication Number Publication Date
WO2018097628A2 WO2018097628A2 (ko) 2018-05-31
WO2018097628A3 true WO2018097628A3 (ko) 2018-08-09

Family

ID=62196019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/013444 Ceased WO2018097628A2 (ko) 2016-11-25 2017-11-23 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법

Country Status (20)

Country Link
US (3) US10485802B2 (ko)
EP (2) EP3800471A1 (ko)
JP (2) JP6663509B2 (ko)
KR (4) KR102519796B1 (ko)
CN (2) CN115025225A (ko)
AU (1) AU2017363804B2 (ko)
BR (1) BR112019009711A2 (ko)
CA (1) CA3041245C (ko)
CL (1) CL2019001415A1 (ko)
DK (1) DK3425390T3 (ko)
ES (1) ES2848720T3 (ko)
HU (1) HUE052854T2 (ko)
IL (1) IL266573B (ko)
MX (1) MX379222B (ko)
MY (1) MY194462A (ko)
NZ (1) NZ754020A (ko)
PH (1) PH12019501143A1 (ko)
SG (2) SG10202105383QA (ko)
WO (1) WO2018097628A2 (ko)
ZA (1) ZA201903226B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3425390T3 (da) * 2016-11-25 2021-02-15 Genuv Inc Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf
US20220313782A1 (en) * 2019-05-02 2022-10-06 Board Of Regents, The University Of Texas System Methods and compositions involving tert activating therapies
CN113874020A (zh) * 2019-05-22 2021-12-31 基诺富公司 使用曲美替尼和标志物治疗神经退化性疾病的给药方法和剂量方案
CN111143763B (zh) * 2019-12-13 2021-09-17 广东电网有限责任公司 电力设备状态的评估方法、装置及其存储介质
KR20230004597A (ko) * 2020-04-14 2023-01-06 주식회사 지뉴브 신경퇴행성질환 치료제에 대한 반응을 평가하기 위한 방법 및 조성물
WO2022045723A1 (ko) * 2020-08-24 2022-03-03 차의과학대학교 산학협력단 신경줄기세포의 도파민 신경세포로의 분화 촉진용 조성물
KR102744286B1 (ko) * 2020-08-24 2024-12-19 차의과학대학교 산학협력단 신경줄기세포의 도파민 신경세포로의 분화 촉진용 조성물
CN112695019B (zh) * 2021-03-23 2021-06-25 翌圣生物科技（上海）有限公司 逆转录酶突变体及其应用
CN115322966B (zh) * 2022-08-19 2024-04-16 山东大学 叶酸钙纳米颗粒的批量制备方法及诱导神经干细胞分化为胆碱能神经元的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090046576A (ko) * 2007-11-06 2009-05-11 한국과학기술원 퇴행성 신경질환 치료제의 스크리닝 방법
KR20090047532A (ko) * 2006-08-18 2009-05-12 르 라보레또레 쎄르비에르 항­아밀로이드 특성을 지니는 화합물을 스크리닝하는 방법
US20120122728A1 (en) * 2009-05-28 2012-05-17 University Of Central Florida Research Foundation, Inc. Method Of Screening Drugs For Reversal Of Amyloid Beta Neurotoxicity

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
MXPA03001218A (es) * 2000-08-11 2003-05-27 Cephalon Inc Metodos para modular proteinas kinasa de linaje multiple y para estudiar compuestos que modulan proteinas kinasa de linaje multiple.
ATE514707T1 (de) * 2002-04-19 2011-07-15 Univ Toronto Immunologisches verfahren und zusammensetzungen für die behandlung der krankheit von alzheimer
US7732203B2 (en) 2002-08-17 2010-06-08 Ajoll University Industry Cooperation Foundation Method for transdifferentiating mesenchymal stem cells into neuronal cells
SI1761528T1 (sl) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
CN101076543A (zh) * 2004-10-13 2007-11-21 阿布林克斯公司 用于治疗和诊断变性神经疾病如阿尔茨海默症的单结构域骆驼抗淀粉样蛋白β的抗体以及包含它的多肽
ZA200703912B (en) 2004-10-20 2008-09-25 Serono Lab 3-arylamino pyridine derivatives
EP1827470A2 (en) * 2004-12-09 2007-09-05 Neuro Therapeutics AB Materials and methods related to dickkopfs (dkk) and neurogenesis
JP4792290B2 (ja) * 2005-12-27 2011-10-12 財団法人 東京都医学総合研究所 神経幹細胞の製造方法
KR20100088342A (ko) * 2009-01-30 2010-08-09 연세대학교 산학협력단 신경줄기세포의 분화 촉진용 조성물
EP2436387B1 (en) * 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
WO2011062013A1 (ja) * 2009-11-18 2011-05-26 国立大学法人徳島大学 神経幹細胞及び／又は神経系前駆細胞への選択的分化誘導剤
KR101211610B1 (ko) 2010-05-10 2012-12-12 주식회사 스템폰즈 Ｂｍｉ１, ＭＥＫ 억제제와 ＧＳＫ 억제제를 이용하여 체세포로부터 배아줄기세포 유사세포로의 역분화를 유도하는 조성물 및 이를 이용한 배아줄기세포 유사세포의 제조방법
US10196606B2 (en) * 2011-12-13 2019-02-05 Unisa Ventures Pty Ltd Method of producing multipotent stem cells
ES2415581B2 (es) 2011-12-20 2014-02-19 Universidad Nacional De Educación A Distancia Compuestos potenciadores del aprendizaje.
US9452215B2 (en) * 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
CN102604894B (zh) * 2012-02-29 2014-07-30 中国科学院广州生物医药与健康研究院 用于制备神经干细胞的培养基及其用途
US9260393B2 (en) 2012-05-30 2016-02-16 Merck Patent Gmbh Solid state forms of N-((S)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
EP3031908B1 (en) * 2013-08-06 2018-12-05 Takeda Pharmaceutical Company Limited Method for producing dopaminergic neurons
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
US9943549B2 (en) * 2015-03-17 2018-04-17 Food Industry Research And Development Institute Isolation of human neural stem cells from amniotic fluid of patients with neural tube defects
US10179132B2 (en) 2015-05-26 2019-01-15 Industry-Academic Cooperation Foundation, Yonsei University Composition for inducing differentiation of multipotent neural stem cells into dopaminergic neurons and method for inducing differentiation of multipotent neural stem cells into dopaminergic neurons by using the same
KR20160138756A (ko) 2015-05-26 2016-12-06 연세대학교 산학협력단 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법
WO2017117386A1 (en) 2015-12-30 2017-07-06 Icahn School Of Medicine At Mount Sinai Methods of treating cancer using network brakes
WO2017161188A1 (en) 2016-03-16 2017-09-21 The Regents Of The University Of California Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
US10731166B2 (en) 2016-03-18 2020-08-04 Caris Science, Inc. Oligonucleotide probes and uses thereof
SG11201808106YA (en) 2016-03-25 2018-10-30 Ab Science Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
CN105796544A (zh) * 2016-04-06 2016-07-27 福州大学 Mapk信号通路抑制剂在制备治疗帕金森药物上的应用
CN105816461B (zh) * 2016-04-06 2018-10-30 福州大学 曲美替尼在制备治疗帕金森症药物上的应用
US11324747B2 (en) 2016-06-07 2022-05-10 Centre For Cellular And Molecular Platforms Methods and compositions for managing neuroinflammation and neurodegeneration
WO2018031707A1 (en) * 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
DK3425390T3 (da) 2016-11-25 2021-02-15 Genuv Inc Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf
WO2018225063A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090047532A (ko) * 2006-08-18 2009-05-12 르 라보레또레 쎄르비에르 항­아밀로이드 특성을 지니는 화합물을 스크리닝하는 방법
KR20090046576A (ko) * 2007-11-06 2009-05-11 한국과학기술원 퇴행성 신경질환 치료제의 스크리닝 방법
US20120122728A1 (en) * 2009-05-28 2012-05-17 University Of Central Florida Research Foundation, Inc. Method Of Screening Drugs For Reversal Of Amyloid Beta Neurotoxicity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KONG, LIANG ET AL.: "The Coumarin Derivative Osthole Stimulates Adult Neural Stem Cells, Promotes Neurogenesis in the Hippocampus, and Ameliorates Cognitive Impairment in APP/PS1 Transgenic Mice", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 38, no. 9, 1 January 2015 (2015-01-01), pages 1290 - 1301, XP055599371, ISSN: 0918-6158, DOI: 10.1248/bpb.b15-00142 *
YAHATA, NAOKI ET AL.: "Anti-amyloid Beta Drag Screening Platform Using Human iPS Cell -derived Neurons for the Treatment of Alzheimer's Disease", PLOS ONE, vol. 6, no. 9, 2011, pages e25788, XP009514174, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0025788 *

Also Published As

Publication number Publication date
DK3425390T3 (da) 2021-02-15
AU2017363804B2 (en) 2021-12-23
KR102114017B1 (ko) 2020-05-22
MX2019006040A (es) 2019-08-21
PH12019501143A1 (en) 2019-12-16
CA3041245A1 (en) 2018-05-31
EP3800471A1 (en) 2021-04-07
US20200046706A1 (en) 2020-02-13
CN115025225A (zh) 2022-09-09
ZA201903226B (en) 2023-12-20
IL266573A (en) 2019-07-31
WO2018097628A2 (ko) 2018-05-31
US11147816B2 (en) 2021-10-19
SG10202105383QA (en) 2021-07-29
SG11201903725UA (en) 2019-05-30
MX379222B (es) 2025-03-10
KR102519796B1 (ko) 2023-04-11
CN109073634A (zh) 2018-12-21
JP2020074796A (ja) 2020-05-21
EP3425390A2 (en) 2019-01-09
KR20210095748A (ko) 2021-08-02
US20180169102A1 (en) 2018-06-21
JP2019513806A (ja) 2019-05-30
EP3425390A4 (en) 2019-12-25
HUE052854T2 (hu) 2021-05-28
NZ754020A (en) 2022-11-25
JP6663509B2 (ja) 2020-03-11
CA3041245C (en) 2022-12-06
KR20200056465A (ko) 2020-05-22
US10485802B2 (en) 2019-11-26
MY194462A (en) 2022-11-30
AU2017363804A1 (en) 2019-06-20
KR20180116235A (ko) 2018-10-24
ES2848720T3 (es) 2021-08-11
BR112019009711A2 (pt) 2019-08-13
EP3425390B1 (en) 2020-12-23
US11701360B2 (en) 2023-07-18
CL2019001415A1 (es) 2019-10-04
CN109073634B (zh) 2022-07-08
KR101892457B1 (ko) 2018-08-31
US20210401844A1 (en) 2021-12-30
IL266573B (en) 2022-03-01

Similar Documents

Publication Publication Date Title
WO2018097628A3 (ko) 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법
WO2016210372A3 (en) Methods to treat neurological diseases
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2017100726A8 (en) Methods for treating huntington's disease
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
WO2018039475A8 (en) Use of pridopidine for treating dystonias
WO2016005328A3 (en) IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
PH12017500706B1 (en) Composition containing extract or fraction of genus justicia plant
WO2017019540A3 (en) Inhibitors of n-linked glycosylation and methods using same
PH12017500615A1 (en) Ophthalmic composition comprising cyclosporine and trehalose
HK1210598A1 (en) Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
WO2017142895A8 (en) Compositions and methods for treating clostridium associated diseases
WO2015075062A3 (en) Method of treating hair
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
WO2016134257A8 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders
WO2017019951A3 (en) Compositions amd methods of treating acne and photoaging
WO2016178510A3 (ko) 진세노사이드 Ｆ1 또는 Ｒｇ3를 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
CA2986376C (en) Poxvirus-derived promoter, and vector comprising same
WO2016135456A3 (en) A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy
WO2017079161A3 (en) Treatment of neurodegenerative disease with sodium chlorite
WO2017005646A8 (en) Methods and pharmaceutical compositions for the treatment of cystic fibrosis
WO2019155360A3 (en) Pharmaceutical composition for treating bacterial and viral infections
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 20187001715

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020187001715

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2017874605

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018554751

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017874605

Country of ref document: EP

Effective date: 20181005

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17874605

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3041245

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019009711

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017363804

Country of ref document: AU

Date of ref document: 20171123

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112019009711

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190513